Cargando…

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection

BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in infants. Nirsevimab is a single-dose monoclonal antibody with extended half-life that was shown to protect preterm infants 29 to < 35 weeks gestation against RSV LRTI. However, mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hammitt, Laura, Dagan, Ron, Yuan, Yuan, Cots, Manuel Baca, Bosheva, Miroslava, Mahdi, Shabhir A, Muller, William J, Zar, Heather J, Brooks, Dennis, Grenham, Amy, Hamrén, Ulrika Wählby, Mankad, Vaishali S, Ren, Pin, Takas, Therese, Heinrichs, Jon, Leach, Amanda, Griffin, M Pamela, Villafana, Tonya L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Late Breaker Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644820/ http://dx.doi.org/10.1093/ofid/ofab466.1649

Ejemplares similares

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
por: Domachowske, Joseph B, et al.
Publicado: (2023)

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
por: Wilkins, Deidre, et al.
Publicado: (2023)

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
por: Simões, Eric A F, et al.
Publicado: (2023)

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
por: Ahani, Bahar, et al.
Publicado: (2023)

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
por: Wilkins, Deidre, et al.
Publicado: (2023)

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
por: Falsey, Ann R, et al.
Publicado: (2021)

89. The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study
por: Faust, Saul N, et al.
Publicado: (2023)

The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
por: Muszbek, N, et al.
Publicado: (2008)

Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy
por: Gorkin, L, et al.
Publicado: (2006)

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
por: Chacra, A R, et al.
Publicado: (2009)

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009)

T-01: Taux élevé d’infections respiratoires virales chez les patients hospitalisés et le personnel soignant, hiver 2014
por: Conort, G., et al.
Publicado: (2014)

2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study
por: Morehouse, Christopher A, et al.
Publicado: (2023)

Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model
por: Voirin, Nicolas, et al.
Publicado: (2021)

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis
por: Turalde-Mapili, Maria Wilma R., et al.
Publicado: (2023)

LB11. Preliminary Findings from a HIV Self-Testing Program among People Who Use Drugs
por: Rose, Michelle, et al.
Publicado: (2021)

LB-12. SARS-CoV-2 RNA and Antibodies among People Experiencing Homelessness and Staying in Shelters or Outdoor Encampments in Denver, Colorado, May-July 2020
por: McCormick, David, et al.
Publicado: (2020)

LB-14. CovidIQ- a Text Message-Based Symptom Surveillance Tracker that Predicts New Areas of Increased Incidence of Covid-19 Disease
por: Reza, Mohammed, et al.
Publicado: (2020)

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
por: Kieffer, Alexia, et al.
Publicado: (2022)

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
por: Levin, Myron J, et al.
Publicado: (2021)

901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants
por: Pamela Griffin, Mary, et al.
Publicado: (2019)

LB9. Longitudinal antibody dynamics in children infected with SARS-CoV-2 through 6 months post-infection
por: Gentles, Lauren E, et al.
Publicado: (2021)

Assessment of Total Antioxidant Capacity in Serum of Heathy and Stressed Hens
por: Cecchini, Stefano, et al.
Publicado: (2020)

Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012–2018*
por: Buchman, Timothy G., et al.
Publicado: (2020)

Sepsis Among Medicare Beneficiaries: 2. The Trajectories of Sepsis, 2012–2018*
por: Buchman, Timothy G., et al.
Publicado: (2020)

Sepsis Among Medicare Beneficiaries: 3. The Methods, Models, and Forecasts of Sepsis, 2012–2018*
por: Buchman, Timothy G., et al.
Publicado: (2020)

LB-6. Increased Diagnoses of Acute HIV Infection through Routine ED Screening and Rapid Linkage to Care and initiation of HAART During the COVID-19 Pandemic
por: Stanford, Kimberly, et al.
Publicado: (2020)

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
por: D'Amico, Ronald, et al.
Publicado: (2020)

LB-11. Comparison of Viral Loads in Individuals With or Without Symptoms At Time of COVID-19 Testing Among 32,480 Residents and Staff of Nursing Homes and Assisted Living Facilities in Massachusetts
por: Lennon, Niall J, et al.
Publicado: (2020)

LB-19. Association between contract staffing and reported outbreaks of SARS-CoV-2 in a cluster-randomized trial of 965 U.S. nursing homes
por: McConeghy, Kevin, et al.
Publicado: (2020)

LB-4. Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by Extended Spectrum β-Lactamase-Producing Enterobacterales
por: Belley, Adam, et al.
Publicado: (2020)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

LB-1. Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial
por: Dunne, Michael W, et al.
Publicado: (2020)

LB-16. Association Between Universal Face Shield in a Quaternary Care Center and Reduction of SARS-COV2 Infections Among Healthcare Personnel and Hospitalized Patients
por: Hemmige, Vagesh, et al.
Publicado: (2020)

LB-15. A Trans-Governmental Collaborative Effort to Independently Evaluate SARS-CoV-2 Serology Assays Using Well-Characterized Sample Panels
por: Shawar, Ribhi, et al.
Publicado: (2020)

LB-2. Relative Effectiveness of aIIV3 versus IIV4 and HD-IIV3 In Preventing Influenza-Related Medical Encounters in Adults ≥65 Years of Age at High Risk for Influenza Complications During the U.S. 2017–2018 and 2018–2019 Influenza Seasons
por: Fischer, Lauren, et al.
Publicado: (2020)

LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD)
por: Ducher, Annie, et al.
Publicado: (2020)

LB-18. Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

LB-17. Efficacy of Hydroxychloroquine (HCQ) for Post-exposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Blinded, Randomized, Controlled Trial
por: Brown, Elizabeth R, et al.
Publicado: (2020)

LB-9. Development of a SARS-CoV2 vaccine, ChAdOx1 nCoV19: immunogenicity and safety in older adults
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k50s1ht7rlv7m3069sen21bgl6